Sarah Cavanaugh Buys Celldex Therapeutics Shares

Sarah Cavanaugh, the Senior Vice President of Corporate Affairs and Administration at Celldex Therapeutics, Inc., purchased 95,000 shares of the company on June 25, 2026. This insider move adds to the significant activity within the company as it continues to develop its therapeutic antibody programs.

Insider Buying and Selling at Celldex Therapeutics, Inc.

Cavanaugh isn't the only insider showing confidence in Celldex. On the same day, several other senior executives also made substantial purchases. Ronald Pepin, Senior Vice President and Chief Business Officer, bought 20,000 shares. Denice Torres and Garry Arthur Neil each acquired 26,000 shares. Meanwhile, Samuel Bates, Senior Vice President and CFO, and Margo Heath-Chiozzi, Senior Vice President of Regulatory Affairs, both purchased 93,000 and 95,000 shares, respectively. These transactions were not part of any pre-planned trading programs.

Celldex Therapeutics, Inc. Stock Down 4.3%

Shares of NasdaqCM:CLDX traded near $35.26 on Tuesday. Celldex Therapeutics has a market cap of approximately $2.77 billion. The company's stock has a 52-week low of $19.52 and a high of $35.79. The 50-day moving average is around $32.10, while the 200-day moving average is approximately $28.27. With a beta of 0.93, the stock shows relatively low volatility compared to the market.

Analysts Set New Price Targets

On June 15, 2026, HC Wainwright & Co. reiterated its buy rating on Celldex, setting a price target of $42. Earlier, on June 10, UBS maintained its buy rating with a target of $45. Other firms like Wells Fargo and Barclays have also maintained buy ratings, with price targets of $54 and $48, respectively. The consensus among analysts is a strong buy, with a mean target price of $57.53.

About Celldex Therapeutics

Celldex Therapeutics, Inc. is a biopharmaceutical company based in Hampton, New Jersey. It focuses on developing therapeutic antibodies for treating severe inflammatory, allergic, autoimmune, and other diseases. The company is advancing various drug candidates, including Barzolvolimab for chronic urticarias and other conditions, and CDX-622, a bispecific candidate targeting chronic inflammation. Led by CEO Anthony S. Marucci, the company employs around 198 people.

Bottom Line

Sarah Cavanaugh's recent purchase of Celldex Therapeutics shares reflects a vote of confidence in the company's ongoing development efforts. Investors often track insider buying as a potential indicator of a company's future prospects. However, it's important to note that these insider trades are part of periodic reports and may not reflect the current insider position.